PDCD1 and Hodgkins lymphoma: Recently, immunotherapy has become mainstream and shown significant efficacy in tumours with PD-1/PD-L1 immunosuppressive mechanisms, such as malignant melanoma, Hodgkin’s lymphoma, and some lung and colon cancers25.